Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study

Maurie Markman, John A. Blessing, Ronald D. Alvarez, Parviz Hanjani, Steven Waggoner, Kevin L Hall

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objectives. The aim of this study was to develop an alternative effective and more convenient administration schedule for intravenous topotecan when used as palliative treatment in ovarian cancer. Methods. The Gynecologic Oncology Group conducted a Phase II trial of 24-h infusional topotecan (8.5 mg/m2) with treatment repeated every 3 weeks in 29 patients with platinum-sensitive recurrent ovarian cancer (prior response to platinum- based chemotherapy with a minimum treatment-free interval ≥6 months). Results. The major toxicities of therapy were grade 4 neutropenia and thrombocytopenia which developed in 86 and 14% of patients, respectively. Other severe side effects were uncommon. Only 2 partial responses (7%) were observed in the 28 patients evaluable for response. Conclusions. Despite the relatively favorable ovarian cancer patient population treated in this trial (platinum-sensitive recurrent disease), the response rate was disappointingly low. Considering the three- to fivefold higher objective response rates observed in other trials employing topotecan in individuals with platinum- sensitive ovarian cancer utilizing a 5-day treatment program (delivered every 3 weeks), the results of the current study provide strong support for the conclusion that clinically relevant antineoplastic activity of this agent is highly schedule dependent. (C) 2000 Academic Press.

Original languageEnglish (US)
Pages (from-to)112-115
Number of pages4
JournalGynecologic Oncology
Volume77
Issue number1
DOIs
StatePublished - Apr 2000

Fingerprint

Topotecan
Platinum
Ovarian Neoplasms
Appointments and Schedules
Therapeutics
Neutropenia
Palliative Care
Intravenous Administration
Antineoplastic Agents
Drug Therapy
Population

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer : A Gynecologic Oncology Group study. / Markman, Maurie; Blessing, John A.; Alvarez, Ronald D.; Hanjani, Parviz; Waggoner, Steven; Hall, Kevin L.

In: Gynecologic Oncology, Vol. 77, No. 1, 04.2000, p. 112-115.

Research output: Contribution to journalArticle

Markman, Maurie ; Blessing, John A. ; Alvarez, Ronald D. ; Hanjani, Parviz ; Waggoner, Steven ; Hall, Kevin L. / Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer : A Gynecologic Oncology Group study. In: Gynecologic Oncology. 2000 ; Vol. 77, No. 1. pp. 112-115.
@article{237f26e875a041c7aca9c11eba0ff503,
title = "Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study",
abstract = "Objectives. The aim of this study was to develop an alternative effective and more convenient administration schedule for intravenous topotecan when used as palliative treatment in ovarian cancer. Methods. The Gynecologic Oncology Group conducted a Phase II trial of 24-h infusional topotecan (8.5 mg/m2) with treatment repeated every 3 weeks in 29 patients with platinum-sensitive recurrent ovarian cancer (prior response to platinum- based chemotherapy with a minimum treatment-free interval ≥6 months). Results. The major toxicities of therapy were grade 4 neutropenia and thrombocytopenia which developed in 86 and 14{\%} of patients, respectively. Other severe side effects were uncommon. Only 2 partial responses (7{\%}) were observed in the 28 patients evaluable for response. Conclusions. Despite the relatively favorable ovarian cancer patient population treated in this trial (platinum-sensitive recurrent disease), the response rate was disappointingly low. Considering the three- to fivefold higher objective response rates observed in other trials employing topotecan in individuals with platinum- sensitive ovarian cancer utilizing a 5-day treatment program (delivered every 3 weeks), the results of the current study provide strong support for the conclusion that clinically relevant antineoplastic activity of this agent is highly schedule dependent. (C) 2000 Academic Press.",
author = "Maurie Markman and Blessing, {John A.} and Alvarez, {Ronald D.} and Parviz Hanjani and Steven Waggoner and Hall, {Kevin L}",
year = "2000",
month = "4",
doi = "10.1006/gyno.2000.5755",
language = "English (US)",
volume = "77",
pages = "112--115",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer

T2 - A Gynecologic Oncology Group study

AU - Markman, Maurie

AU - Blessing, John A.

AU - Alvarez, Ronald D.

AU - Hanjani, Parviz

AU - Waggoner, Steven

AU - Hall, Kevin L

PY - 2000/4

Y1 - 2000/4

N2 - Objectives. The aim of this study was to develop an alternative effective and more convenient administration schedule for intravenous topotecan when used as palliative treatment in ovarian cancer. Methods. The Gynecologic Oncology Group conducted a Phase II trial of 24-h infusional topotecan (8.5 mg/m2) with treatment repeated every 3 weeks in 29 patients with platinum-sensitive recurrent ovarian cancer (prior response to platinum- based chemotherapy with a minimum treatment-free interval ≥6 months). Results. The major toxicities of therapy were grade 4 neutropenia and thrombocytopenia which developed in 86 and 14% of patients, respectively. Other severe side effects were uncommon. Only 2 partial responses (7%) were observed in the 28 patients evaluable for response. Conclusions. Despite the relatively favorable ovarian cancer patient population treated in this trial (platinum-sensitive recurrent disease), the response rate was disappointingly low. Considering the three- to fivefold higher objective response rates observed in other trials employing topotecan in individuals with platinum- sensitive ovarian cancer utilizing a 5-day treatment program (delivered every 3 weeks), the results of the current study provide strong support for the conclusion that clinically relevant antineoplastic activity of this agent is highly schedule dependent. (C) 2000 Academic Press.

AB - Objectives. The aim of this study was to develop an alternative effective and more convenient administration schedule for intravenous topotecan when used as palliative treatment in ovarian cancer. Methods. The Gynecologic Oncology Group conducted a Phase II trial of 24-h infusional topotecan (8.5 mg/m2) with treatment repeated every 3 weeks in 29 patients with platinum-sensitive recurrent ovarian cancer (prior response to platinum- based chemotherapy with a minimum treatment-free interval ≥6 months). Results. The major toxicities of therapy were grade 4 neutropenia and thrombocytopenia which developed in 86 and 14% of patients, respectively. Other severe side effects were uncommon. Only 2 partial responses (7%) were observed in the 28 patients evaluable for response. Conclusions. Despite the relatively favorable ovarian cancer patient population treated in this trial (platinum-sensitive recurrent disease), the response rate was disappointingly low. Considering the three- to fivefold higher objective response rates observed in other trials employing topotecan in individuals with platinum- sensitive ovarian cancer utilizing a 5-day treatment program (delivered every 3 weeks), the results of the current study provide strong support for the conclusion that clinically relevant antineoplastic activity of this agent is highly schedule dependent. (C) 2000 Academic Press.

UR - http://www.scopus.com/inward/record.url?scp=0034006137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034006137&partnerID=8YFLogxK

U2 - 10.1006/gyno.2000.5755

DO - 10.1006/gyno.2000.5755

M3 - Article

C2 - 10739699

AN - SCOPUS:0034006137

VL - 77

SP - 112

EP - 115

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -